Highlights of the full report
- A first complete overview of the European public biotech sector: With reference to the internationally comparable biotech definition of the Organisation for Economic Co-operation and Development (OECD) financial key data of all listed dedicated biotech firms – from drug developers to enzyme producers – were recorded and analysed
- An analysis of the most important trading centres in Europe with relevance for the biotech sector with respect to the number and amounts of IPOs and follow-on financings from 2011 until 2016
- SPECIAL: Analysis of European biotech companies on NASDAQ and comparison with European exchanges
